NEW YORK (GenomeWeb) – Interleukin Genetics reported today that its revenues for the fourth quarter of 2014 fell by more than 50 percent to $322,005 from $671,049 year over year.

The decrease was due to less deferred revenue recognized from PerioPredict test kit sales and recognized license fee income, the firm said.

Genetic testing revenues for the quarter were $298,543 compared to $424,401 in the year-ago Q4, while other revenues were $23,462 in Q4 2014 compared to $246,648 in the fourth quarter of 2013.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.